Mammoth Biosciences is a biotechnology company that develops CRISPR-based platform for diagnostics, democratizing access to an endless variety of tests for sensing in healthcare.
Mammoth Biosciences is harnessing the diversity of nature to power the next generation of CRISPR products.
Mammoth Biosciences was founded in 2017 by Jennifer Doudna, Trevor Martin, Janice Chen and Lucas Harrington. The company is headquartered in San Francisco, California.
Mammoth's revolutionary method for molecular diagnostics, enabling limitless testing possibilities. The company's CRISPR-Cas systems provide unprecedented power to edit the genome.
Mammoth is addressing the current challenges of CRISPR-Cas systems and expanding the scope of use by applying our proprietary discovery platform to identify novel Cas proteins.
Mammoth Biosciences is backed by Mayfield, NFX, Decheng Capital, 8VC, AME Cloud, Wireframe and others. The company raised $45M in a Series B financing on Jan 30, 2020. This brings Mammoth's total funding to $70M to date.